Eyevensys SAS:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Eyevensys SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11262
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eyevensys SAS (Eyevensys) is a clinical stage biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its lead product, EYS-606, is a soluble TNFa receptor plasmid associated with the ETIS device to treat non-infectious intermediate and posterior uveitis(NIU); EYS-609, is a device-plasmid combination method to express anti-VEGF compound for treating age-related macular degeneration (AMD), and retinopathies, including Central Retinal Vein Occlusion (RVO) and Diabetic Retinopathy (DR/DME); and EYS-611 for retinal degeneration. Eyevensys’ EyeCET platform is a non-viral technology utilizing ETIS (Electro-Transfection Injection System) device to deliver plasmids encoding for the production therapeutic proteins in the ciliary muscle. The company works in partnership with organizations such as Eurogentec, Declic, Fesys and CytoxLab to validate its platform technology. Eyevensys is headquartered in Paris, France.

Eyevensys SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eyevensys SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eyevensys SAS, Medical Devices Deals, 2012 to YTD 2018 9
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eyevensys SAS, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Eyevensys Raises Additional Funds in Series A Financing 11
Eyevensys Secures Venture Funding 12
Eyevensys Raises Funds In Second Round Of Financing 13
Eyevensys Raises US$2 Million In First Round Of Financing 14
Eyevensys SAS – Key Competitors 15
Eyevensys SAS – Key Employees 16
Eyevensys SAS – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Dec 12, 2017: Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer 18
Sep 04, 2017: Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer 19
Mar 21, 2017: Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman 20
Product News 21
05/09/2017: Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases 21
04/20/2017: Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development 22
04/11/2017: Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Eyevensys SAS, Pharmaceuticals & Healthcare, Key Facts 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eyevensys SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eyevensys SAS, Deals By Therapy Area, 2012 to YTD 2018 8
Eyevensys SAS, Medical Devices Deals, 2012 to YTD 2018 9
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eyevensys Raises Additional Funds in Series A Financing 11
Eyevensys Secures Venture Funding 12
Eyevensys Raises Funds In Second Round Of Financing 13
Eyevensys Raises US$2 Million In First Round Of Financing 14
Eyevensys SAS, Key Competitors 15
Eyevensys SAS, Key Employees 16

List of Figures
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eyevensys SAS, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Eyevensys SAS:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Novartis Pharmaceuticals Corp-製薬・医療分野:企業M&A・提携分析
    Summary Novartis Pharmaceuticals Corp (Novartis), a subsidiary of Novartis AG is a developer, manufacturer and distributor of active ingredients, patent protected medicines and treatments for the healthcare industry. The company’s products include innovative prescription medicine and drugs, tablets, …
  • Kobayashi Pharmaceutical Co Ltd (4967):医療機器:M&Aディール及び事業提携情報
    Summary Kobayashi Pharmaceutical Co Ltd (Kobayashi) is a manufacturer and distributor of pharmaceutical, health and personal care products. The company offers OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, cooling gel sheets, sanitary products, household sundries, and body w …
  • Sound Energy Plc (SOU):石油・ガス:M&Aディール及び事業提携情報
    Summary Sound Energy Plc (Sound Energy), formerly Sound Oil plc is an upstream oil and gas company that offers exploration and development of oil and gas properties in Europe and Africa. The company holds interests, owns, and operates the Badile permit located in the Piedmont Lombard Basin in northe …
  • AnaMar AB:医療機器:M&Aディール及び事業提携情報
    Summary AnaMar AB (AnaMar), a subsidiary of Koncentra Holding AB, is a drug discovery company that discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. The company develops drug candidates from several chemical classes on the receptors …
  • Vectura Group Plc (VEC)-医療機器分野:企業M&A・提携分析
    Summary Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) …
  • Crane Co (CR):企業の財務・戦略的SWOT分析
    Crane Co (CR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Canpotex Ltd:企業の戦略的SWOT分析
    Canpotex Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • CUNA Mutual Group:企業の戦略・SWOT・財務情報
    CUNA Mutual Group - Strategy, SWOT and Corporate Finance Report Summary CUNA Mutual Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • An Binh Commercial Joint Stock Bank:企業の戦略的SWOT分析
    An Binh Commercial Joint Stock Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • CF Industries Holdings, Inc:企業のM&A・事業提携・投資動向
    CF Industries Holdings, Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CF Industries Holdings, Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Marinus Pharmaceuticals Inc (MRNS):企業の財務・戦略的SWOT分析
    Summary Marinus Pharmaceuticals Inc (Marinus) is a clinical stage biopharmaceutical company that manufactures and commercializes therapeutics for the treatment of epilepsy, neuropsychiatric disorders and others diseases. The company’s pipeline product comprise ganaxolone is a CNS-selective GABAA mod …
  • BlackRock Inc:企業の戦略・SWOT・財務情報
    BlackRock Inc - Strategy, SWOT and Corporate Finance Report Summary BlackRock Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • NV Nederlandse Gasunie:企業の戦略的SWOT分析
    NV Nederlandse Gasunie - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Bristow Group, Inc.:戦略・SWOT・企業財務分析
    Bristow Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bristow Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Diagnostica Stago SAS:企業の戦略的SWOT分析
    Diagnostica Stago SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Karnataka Power Corporation Ltd:企業の戦略的SWOT分析
    Karnataka Power Corporation Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • C.H. Bailey PLC:企業の戦略・SWOT・財務分析
    C.H. Bailey PLC - Strategy, SWOT and Corporate Finance Report Summary C.H. Bailey PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sirtex Medical Ltd (SRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Sirtex Medical Ltd (Sirtex Medical) is a medical device company that develops and markets device for the treatment of liver cancer. The company’s sir-spheres microsphere is a medical device, which is used in selective internal radiation therapy for liver tumors. Its product Y-90 resin micros …
  • Empyrean Energy PLC (EME):企業の財務・戦略的SWOT分析
    Summary Empyrean Energy PLC (Empyrean Energy) is an oil and gas exploration and production company that acquires, explores and develops oil and gas properties. The company's projects include China Block 29/11 project, Duyung PSC project, and Sacramento Basin Projects. Its Duyung PSC project covers a …
  • Weight Watchers International, Inc. (WW):企業の財務・戦略的SWOT分析
    Weight Watchers International, Inc. (WW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆